Epilepsy Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2019 – 2028

Overview

The global Epilepsy market is projected to grow at a CAGR of 7.8% during the forecast period, 2021 – 2028. The Global Epilepsy Market report provides a proper evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a vital role in the market.

Epilepsy is a neurological disorder in which the brain functions abnormally, the patient behaves in a sensitive and strange way as function of the brain cells is disturbed. The patient loses its ability to do things on their own and needs assistance all the time. It is fourth most common disorder and can be developed by anyone be male or female. Epilepsy is a dreadful neurological disorder causing unprovoked, periodic seizures which may be deadly sometimes. A seizure is an explosion of uncontrollable electric currents between the brain cells or nerve cells. Seizures are of two types – Generalized and Focal. Generalized seizures strikes the whole brain whereas, Focal seizures affect just one part of the brain and are called partial seizures. A mild seizure lasts for few seconds and often goes un-noticed. Some of the stronger seizures can cause spasms and uncontrollable muscle twitches, and can last a few seconds to several minutes. During a stronger seizure, some people become confused or lose consciousness and you may have no memory of it happening. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and so much more. Public perception and treatment of people with epilepsy are often bigger problems than actual seizures. Around 65 million people in the world have Epilepsy, where the number in the U.S. itself is 3.3 million. 80% of the epileptic patients are from low-income families and cannot afford good treatment, if given proper diagnosis 70% of the patients can live a seizure free normal life.

Market Dynamics

The major factors which cause growth in the global Epilepsy market are the increase in the number of accidents and brain injuries and the higher rate of post-traumatic seizure occurrence in patients with brain injuries, factors like the growing awareness among the people, fundings from the government, invention of new and advanced ways of treatment and diagnosis, availability of the medicines like Levetiracetam, Fycompa (perampanel), valproates, carbamazepine, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), marks certain hike in the Epilepsy market.

Currently available antiepileptic drugs have limited efficacy, because they are very costly and their negative properties limit their use and cause difficulties in patient management. Antiepileptic drugs can provide only symptomatic relief as these drugs suppress seizures and have no effect on the epileptogenesis, which is a process that converts the normal circuitry of the brain into a hyperexcitable one, often after an injury. We cannot use antiepileptic drugs for a long time because they cause serious adverse effects and they show withdrawal symptoms. Side effects when used with other drugs and cost-effectiveness especially in developing countries are some of the key factors responsible for restraining the global Epilepsy market. Despite huge funding, and extensive premarketing testing for the adverse effects of new antiepileptic drugs, they may still show severe side effects after being introduced on to the market severe side effects may go unnoticed during these trials.

Epilepsy market size will flourish due to the several Epilepsy centers that are working towards recognizing and addressing pseudo-pharmaco-resistance faced by patients due to antiepileptic medications (AEDs), increase in the research rate because of the growing number of patients and government funding. Also, the Epilepsy pipeline possesses several high phase drugs, with Libervant and Ganaxolone being the best ones with impressive results.

The biggest challenge in the global Epilepsy market is that the treatment and diagnosis are way more costly. Another biggest challenge is managing the patients as even after the treatment they are likely to show the symptoms and behave abnormally. The social life of the patient gets restricted and the patient loses the right to drive as well which may affect their education, and job opportunities. One of the most significant challenge is that there is no clinical evidence to support one drug technique or the first drug technique. Therefore, treatment should be individualized and the treatment should be according to the seizure type, clinical profile and preference.

Market Segmentation

The Epilepsy market is segmented on the basis of Condition, Diagnosis &Treatment and end-user. On the basis of condition, the Epilepsy market is bifurcated into Epilepsy Drug Resistant and Intractable Epilepsy. The resistant epilepsy held 25.5% in 2017 and is expected to exceed with a great extent. In Diagnosis, several tests are taken such as the Electroencephalography (EEG) which are of two types – Routine EEG and Prolonged EEG, and the Radiologic Testing Some seizures and epilepsies are due to irregularities within the brain tissue, such as scars and tumors that can show up on radiologic imaging. Some of these issues can be treated with epilepsy surgery. Radiologic tests include – Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET). A brain scan called an interictal fluorodeoxyglucose (FDG) PET scan can show changes in brain metabolism and chemistry, which is valuable in evaluating patients with many different conditions affecting the brain, especially epilepsy. Treatment in Epilepsy includes medicines, and a nice balanced diet along with providing a good environment to the patient. Some of the good medicine in the treatment of Epilepsy are Carbamazepine, Valproic acid (Depakene), Lamotrigine (Lamictal), Gabapentin, Topiramate (Topamax), and Phenobarbital. UCB Pharma Ltd., Abbott Laboratories, Inc., Sanofi S. A, are some of those companies which are ruling the global market.

Geography Analysis

Region-wise, the epilepsy market is segmented into Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). Among them, the Americas accounted for 41% share in 2017, followed by Europe, APAC, and MEA. Europe is expected to exhibit 8.31% CAGR over the forecast period. The Main reason behind the growth of the market over the segments is the exceeding need of proper treatment. APAC epilepsy market is set to touch a valuation of USD 000000 million by 0000 due to high incidence of the disorder registered in the region. In addition, countries like India, South Korea, and China are shining as the hub of testing and development of novel drugs, which can spur market demand over the forecast period.

Some of the prominent key players in the Epilepsy market are Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., LivaNova PLC.

Market Segmentation and Scope of Epilepsy Market

  • By Condition
    • Drug resistant
    • Intractable Epilepsy
  • By Diagnosis
    • Electroencephalography (EEG)
    • Routine EEG and
    • Prolonged EEG
    • Radiologic Testing
    • Magnetic Resonance Imaging (MRI)
    • Positron Emission Tomography (PET)                                                     
  • By Region
  • North America
    • US
    • Canada
    • Europe
      • Germany
      • UK
      • France
      • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of the World

Key Players

  • Abbott Laboratories,
  • GlaxoSmithKline PLC.,
  • Sunovion Pharmaceuticals Inc.,
  • Johnson & Johnson,
  • Novartis AG,
  • Takeda Pharmaceutical Company Limited,
  • Pfizer Inc.,
  • LivaNova PLC.
Back to top

Payment Options

Single User $3971.25
$5295
Five User $4646.25
$6195
Enterprise $6149.25
$8199
Datapack $1649.25
$2199
Short Report: $2324.25
$3099